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1. Introduction 
Breast cancer is the most prevailing malignancy among women in the world. 207,090 new 
cases of invasive breast cancer, along with 54,010 new cases of non-invasive types are 
expected to be diagnosed in women in the United States in 2010. Moreover, about 39,840 
women are projected to die from this disease in the U.S in 2010. According to National 
Cancer Institute, the 5-year survival rate of breast cancer ranges from 23.4% in patients with 
stage IV to 98% in patients with stage I, highlighting the importance of early detection and 
diagnosis of this disease(American Cancer Society, 2010).  
Molecular imaging does not only serve as an essential tool in breast cancer diagnosis and 
staging, but also provides significant amount of information for surgical management, 
radiation planning, chemotherapeutic assessment, and follow-up evaluation of patients. 
Currently, positron emission tomography (PET), single photon emission computed 
tomography (SPECT), and their combinations with CT, are major functional molecular 
imaging modalities used in clinic. Both PET and SPECT are based on the detection of 
radiolabeled ligands, termed “radiotracers”, which are assumed to target tumor-specific 
characteristics at molecular levels. The accumulating understanding of the breast cancer 
molecular biology has highlighted pivotal factors that are critical for breast cancer 
progression, which allows researchers to select suitable targets for developing tumor-
specific radiotracers. For instance, given that sustained tumor growth demands elevated 
glucose consumption for energy production in the lesion regions, PET radiotracer 18F-
labeled glucose analog 18F-FDG has commonly been used to visualize the glucose 
metabolism of breast cancer cells(Buerkle & Weber, 2008). And yet, 18F-Fluoroestradiol is 
used to image estrogen receptor, which is highly overexpressed in a large proportion of 
breast tumor tissues(Jonson & Welch, 1998). Many other radiotracers have been designed to 
image cell proliferation, cell apoptosis, angiogenesis and hypoxia of breast tumors. Since 
breast cancer treatment has become more individualized in compliance with the distinct 
biological characteristics of tumors from each patient, the more target-specific molecular 
imaging radiotracers may play a key role to guide treatment selection and evaluate 
treatment response in the early stages. 
This chapter has firstly been focused on two major molecular imaging modalities, PET and 
SPECT, their principles, limitations, as well as the typical radionuclides applied for those 
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modalities. The most commonly-used radiotracers, 18F-FDG for PET and 99mTc-sestamibi for 
┛-imaging, have then been reviewed, respectively. In the following sections, we have 
discussed the radiotracers currently applied for breast cancer imaging other than 18F-FDG 
and 99mTc-sestamibi, such as radiolabeled trastuzumab targeting HER2 receptor and 18F-
fluorothymidine imaging cell proliferation. Those radiotracers have been described 
according to the categories of the tumor-specific targets.   
2. Molecular imaging modalities and radionuclides  
2.1 Positron emission tomography (PET) and its radionuclides 
Positron emission tomography (PET) is a 3-D nuclear medicine imaging technique, which is 
based on detection of the annihilation radiation emitted from a certain positron-emitting 
radionuclide(Buerkle & Weber, 2008). When the radionuclide decays, the positron will 
annihilate with an electron nearby, thus create two 511 keV photons emitted opposite to 
each other (180 degree). This process is called “coincidence event”, which can be observed 
by PET detectors arranged in an array of full or partial ring around the patient body axis. 
Data are then reconstructed using standard algorithm. By using this coincidence-detection 
method, the traditional collimator of the SPECT scanner can be removed, therefore, the 
spatial resolution and sensitivity can be highly improved.  
Commonly used PET imaging radionuclides are listed in Table 1. In order to monitor a small 
bioactive molecule in vivo without changing its chemical structure, 11C is often labeled as a 
substitute for the stable carbon atom 12C in that molecule. Given that 11C has only 20 min 
half-life, 18F can then be an alternative. In fact, 18F is currently the most frequently 
used/developed PET radionuclide. The best example of 18F-based radiotracers, 18F-labeled 
glucose analogue 18F-FDG, has been discussed in the next section. In addition to 11C- and 
18F-labeled biomarkers, there are some other “non-targeted” radiotracers such as 15O-labeled 
water and 13N-labeled ammonia that measure blood flow in the patient body(Wijns & 
Camici, 1997). Moreover, copper-64 (64Cu) and zirconium-89 (89Zr), because of their long 
half-life (12.7 h and 78.4 h, respectively), have been increasingly recognized in the past 
decade for labeling nanoparticles or slowly localizing antibodies(DeNardo, 2005). Other 
than those cyclotron-produced PET radionuclides mentioned above, generator-produced 
gallium-68 (68Ga) and rubidium-82 (82Rb) have also shown high potentials in PET imaging. 
The advantage of in-house generator produced radionuclide is that generator itself serves as 
a top-of-the-bench source for short half-life radionuclides in the places that are located far 
from the cyclotron facility. Besides, it is quite simple to obtain radionuclides from the 
generator, and less expensive compared to cyclotron-produced radionuclides. 
2.2 Single photon emission computed tomography (SPECT) and its radionuclides 
Single photon emission computed tomography (SPECT) is a widely used nuclear medicine 
imaging modality, which utilizes radiotracers emitting gamma-ray photons directly from 
the labeling radionuclide. The energy of the radionuclide is generally from 70 to 364 keV 
(Table 2). A typical SPECT system consists of one or more rotating gamma camera(s) to 
obtain multiple projection images from different views around the patient, and a computer 
algorithm for 3D image reconstruction. A collimator is required to collect the ┛-ray photons 
that only are emitted from the patient body in a particular direction(Benard & Turcotte, 
2005). 
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Table 1. Radionuclides commonly used in PET imaging. 
 
 
Table 2. Radionuclides commonly used in SPECT imaging (IT: isomeric transition, EC: 
electron capture). 
Technetium-99m (99mTc, t1/2=6.02 h) is the most common radionuclide for SPECT imaging. It 
emits a 140 keV gamma ray in 89% abundance, which can be detected by NaI detectors. In 
addition, it is produced with in-house generator that contains the parent nuclide 
molybdenum-99 (99Mo), and does not require the cyclotron. Since the chemistry of 
diagnostic radionuclide 99mTc is very similar to that of the therapeutic radioisotope rhenium-
188 (188Re), they could be labeled to the same ligand, which leads to the 
diagnostic/therapeutic matched pair(Schechter et al., 2007).  
Radionuclide Half-life Production
11C 20.4 min Cyclotron
13N 9.97 min Cyclotron
15O 2.03 min Cyclotron
18F 109.7 min Cyclotron
64Cu 12.8 h Cyclotron
89Zr 78.4 h Cyclotron
68Ga 68 min Generator
82Rb 1.25 min Generator
Radionuclide Decay Mode Half-life Emitted Photon Energy [keV] 
99mTc IT 6.01 h 140 (87.7%)
201Tl EC 73.0 h 71 (47%), 135 (3%), 167 (10%)
123I EC 13.2 h 159 (83.3%)
131I Β- 8.02 d 364 (81.2%)
111In EC 67.4 h 171(90.3%), 245 (94%)
67Ga EC 78.3 h 93 (37%), 184 (20.4%), 300 (16.6%)
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Although the resolution and sensitivity of SPECT is not as good as PET scan due to its 
physical nature, SPECT and SPECT/CT still play important and irreplaceable roles in 
nuclear imaging area. First of all, SPECT radiopharmaceuticals are comparatively easier and 
less costly to produce. In addition, given that most SPECT radionuclides have longer half-
life than PET radionuclides, SPECT offers more possibility to broaden the observational time 
window that allows the doctors to monitor biological processes in vivo several hours or even 
days after radiopharmaceutical administration. Furthermore, only limited facilities around 
the world can afford complete armamentarium of PET instruments and cyclotron for the 
local production of short-lived positron-emitters. Clinical data have shown that 15.9 million 
SPECT procedures were performed in 2007, while only 1.6 million of PET procedures were 
performed, in comparison(Mariani et al., 2008). 
3. The most common radiotracers for breast cancer imaging in clinic 
3.1 
18
F-FDG for PET/CT and PEM (positron emission mammography) 
In recent years, 18F-fluoro-deoxy-glucose (18F-FDG), which is an 18F-labeled analog of 
glucose, has become the most common and attractive radiotracer for PET scans. Both 18F-
FDG and glucose are transported across the cell membrane by glucose transporters. 18F-FDG 
is phosphorylated by hexokinase to 18F-FDG-6-phosphate while glucose is phosphorylated 
to glucose-6-phosphate. Unlike glucose-6-phosphate, 18F-FDG-6-phosphate cannot be 
further metabolized, and therefore, is trapped and accumulates steadily in the tumor 
cells(Buerkle & Weber, 2008). Hence, 18F-FDG is able to provide high sensitivity and 
specificity for detecting, staging, and restaging tumors by imaging high glucose metabolic 
rates in tumor cells. For breast cancer cells, increased glucose utilization is caused by the 
overexpression of glucose transporters Glut-1/3 and increased hexokinase activity. The rate-
limiting step in the uptake of 18F-FDG in breast cancer appears to be the phosphorylation 
process by hexokinase, particularly hexokinase I(Buck et al., 2004).  
Although 18F-FDG-PET generally has high sensitivity and specificity in detecting 
malignancies, whole-body 18F-FDG-PET is not quite suitable for primary breast cancer 
diagnosis, especially for the low grade tumors and tumors with a size less than 1 cm in 
diameter(Lim et al., 2007). In addition, it is not appropriate for breast cancer screening as 
well. Therefore, 18F-FDG with positron emission mammography (PEM) has been introduced 
as an alternative. In comparison with PET, PEM has a much higher spatial resolution by 
putting two opposite detector heads on each side of the breast and thus minimizing the 
distance between radiation source and the detectors. Schilling et al. have reported that PEM 
can detect tumor as small as 1.5 mm in diameter, with much less breast compression 
compared to traditional mammography(Schilling et al., 2011). They have also indicated that 
PEM is not affected by breast density and it has good sensitivity (90%) in detecting ductal 
carcinoma in situ (DCIS), which cannot be detected by PET very well.  
For breast cancer logoregional staging, 18F-FDG-PET has shown high sensitivity in axillary 
staging of late-stage cancer patients, but not sensitive enough in detecting the early-stage 
micrometastases and small tumor-infiltrated axillary lymph nodes(Aukema et al., 2010). 
Therefore, 18F-FDG-PET is not sufficient to replace the sentinel lymph node (SLN) biopsy in 
this case. Instead, 18F-FDG-PET appears to be suitable for distant (systemic) staging, as well 
as for staging locally advanced breast cancer (LABC) because LABC usually has large 
primary tumor (> 5 cm in diameter) or advanced axillary disease without clinically apparent 
distant metastases(Mahner et al., 2008). Moreover, several studies have demonstrated that 
www.intechopen.com
 
Radiotracers for Molecular Imaging of Breast Cancer 267 
18F-FDG-PET is superior to traditional bone scintigraphy in the detection of osteolytic and 
intramedullary metastases but inferior in the detection of primary osteoblastic 
lesions(Schirrmeister, 2007). 
An increasing number of studies have been performed to evaluate treatment response using 
18F-FDG-PET. Although 18F-FDG has not been recommended as a routine assessment agent 
yet, it has been proven to be an accurate early predictor of poor response to therapy. 
Patients with a high 18F-FDG uptake associated with low blood flow/perfusion rate in their 
tumors were more likely to have poor response and early relapse(Tseng et al., 2004).  
3.2 
99m
Tc-sestamibi for scintimammography and BSGI (breast-specific γ-imaging) 
99mTc-methoxyisobutylisonitrile (99mTc-MIBI or 99mTc-sestamibi) scintimammography has 
been increasingly used to assess the suspicious lesions of patients with a negative or 
indeterminate mammography in the clinic(Filippi et al., 2006). This small lipophilic cation 
was originally developed as a myocardial perfusion agent. The first report of its application 
in breast cancer detection was by Aktolun et al. in 1992(Aktolun et al., 1992). The cellular 
uptake mechanisms of 99mTc-sestamibi still remain unclear; however, its uptake is driven by 
a negative transmembrane potential and most of the radioactivity is found in the 
mitochondria(Scopinaro et al., 1994). 99mTc-sestamibi scintimammography shows higher 
sensitivity (85%) and specificity (87%) than the traditional mammography, and its 
sensitivity is independent of breast density(Liberman et al., 2003). In addition, 99mTc-
sestamibi is a substrate of the transmembrane P-glycoprotein (Pgp), which is a member of 
the MDR/TAP subfamily that is involved in the multidrug resistance. Therefore, the uptake, 
clearance, and retention of 99mTc-sestamibi have been investigated as predictors of response 
to chemotherapy in human breast cancer(Kim et al., 2006). In a study of 45 patients with 
primary breast cancer, Cayre et al concluded that a negative 99mTc-sestamibi 
scintimammography predicted chemoresistance with a specificity of 100%. Besides, 99mTc-
sestamibi uptake was inversely correlated to the expression of multidrug resistance protein 
MDR1 (P<0.05) in invasive ductal carcinomas(Cayre et al., 2002). 
Nevertheless, 99mTc-sestamibi scintimammography demonstrates relatively low sensitivity 
in detecting the nonpalpable lesions or tumors smaller than 1 cm. Therefore, the high 
resolution small field-of-view breast-specific ┛-imaging (BSGI) has been developed as an 
alternative. Similar to PEM, the single-head detector used in BSGI is mounted opposite to a 
compression plate, so the patient’s breast is compressed between detector and plate. 
According to a 6-year BSGI study performed by Hruska et al. at Mayo Clinic, the sensitivity 
of BSGI for tumors larger than 1 cm was 97%, while that for tumors smaller than 1 cm was 
74%(Hruska et al., 2008). When compare BSGI with PEM, although the average sensitivity of 
PEM (93%) is slightly higher than that of BSGI (89%), BSGI has a much higher negative 
predictive value (100%) than that of PEM (88%)(Ferrara, 2010). Thus, both of the imaging 
modalities have great detection ability in existing studies, and there is no proven clinically 
significant advantage to either modality over the other so far. 
4. Other radiotracers imaging breast cancer molecular biomarkers  
4.1 Radiotracer targeting hormone receptors 
18F-Fluoroestradiol (18F-FES) targets Estrogen receptor (ER) 
More than 70% of the breast tumors are positive for hormone receptors such as estrogen 
receptor (ER+), and ER-directed breast cancer therapeutic agents such as tamoxifen and 
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aromatase inhibitors are highly effective to these patients with fewer side effects, while 
compared to the traditional chemotherapy(Oude Munnink et al., 2009). To date, 18F-16┙-17┚-
fluoroestradiol (18F-FES) has been proven to be the most successful PET radiotracer in 
determining ER status and prognosis of ER-directed hormonal therapy in breast cancer 
patients(Jonson & Welch, 1998). 
For clinical use, an automated synthesis of 18F-FES can be achieved in a decay-corrected 
yield of 30% at 60 minutes after end of bombardment with high radiochemical purity 
(>99%)(Romer et al., 2001). 18F-FES has a high binding affinity to ER, especially the ER┙ 
subtype(Yoo et al., 2005). In both human and rodents, 18F-FES is rapidly taken up and 
metabolized by the liver. By 20 min after injection, 80% of the 18F-FES is converted to 
radiolabeled glucuronide and sulfate conjugates in blood. The recommended injection dose 
and imaging time of 18F-FES is 6mCi at 30 min after injection(Sundararajan et al., 2007). 
Peterson et al demonstrated excellent agreement (r=0.99) between 18F-FES-PET and ER 
expression assayed by immunohistochemistry (IHC) in 17 patients. In addition, their study 
indicated that ER- tumors in those patients had partial-volume-corrected SUV of less than 
1.0, while that of ER+ tumors were above 1.1(Peterson et al., 2008).  
4.2 Radiotracers imaging HER 2 
Radiolabled trastuzumab 
Human epidermal growth factor receptor 2 (HER2) is a transmembrane glycoprotein that 
forms heterodimers with other EGFR family members to activate distinct signaling pathways, 
which are involved in cell growth, survival, differentiation, adhesion, and migration. HER2 
has been found to be overexpressed in many types of cancers. For breast cancer patients, about 
25-30% of breast tumors have HER2/neu gene amplification and/or HER2 protein 
overexpression(Moasser, 2007). Therefore, HER2 has become an attractive target for breast 
cancer imaging and treatment. The humanized monoclonal antibody trastuzumab has been 
successfully used for HER2-positive breast cancer treatment. By labeling trastuzumab with 
different radionuclides, we can assess the HER2 expression and localization in breast cancer 
patients non-invasively, and thus, select the patients with HER2-positive tumors that are 
qualified for trastuzumab treatment(Capala & Bouchelouche, 2010).  
Zirconium-89 (89Zr; t1/2= 78.41 h) has been chosen for trastuzumab labeling because it has 
the longest half-life among the positron-emitting radionuclides, which allows PET imaging 
up to 7 days after injection(Holland et al., 2009). The antibodies like trastuzumab often have 
high molecular weight, thus slow metabolism and clearance. Hence, longer half-life 
radionuclides are more suitable to obtain better tumor-to-blood ratios even several days 
post injection. Dijkers et al have performed their first clinical trial of 89Zr-trastuzumab PET in 
14 patients with HER2-positive metastatic breast cancer. They have determined the optimal 
imaging time and dose as 4-5 days post injection and 50 mg dose for trastuzumab-naïve 
patients or 10 mg dose for patients already on trastuzumab treatment, respectively(Dijkers 
et al., 2010). Other than 89Zr, trastuzumab has also been labeled with 124I, 86Y, and 76Br for 
PET(Orlova et al., 2009; Winberg et al., 2004; Xu et al., 2007). In addition, the antibody has 
been labeled with 111In for SPECT imaging(Sampath et al., 2007). To date, only 89Zr and 111In-
labeled trastuzumab have been applied to human in the clinical trials. Although the tumor 
uptake levels of 89Zr-trastuzumab and 111In-trastuzumab were similar, 89Zr-labled 
counterpart demonstrated better image quality due to higher spatial resolution and 
sensitivity of PET. 
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4.3 Radiotracer imaging cell proliferation 
18F-fluorothymidine (18F-FLT) 
18F-fluoro-3’-deoxy-3’-L-fluorothymidine (18F-FLT) is a nucleoside-based radiotracer that  
was developed to target DNA replication and cell proliferation in tumors in 1998(Shields et 
al., 1998). 18F-FLT enters the tumor cells mainly by Na+-dependent active nucleoside 
transporters, which are generally upregulated in tumor cells(Reske & Deisenhofer, 2006). 
The same as thymidine, 18F-FLT follows the salvage pathway of DNA synthesis and 
undergoes phosphorylation by thymidine kinase 1 (TK1). Since the 3’-hydroxyl group is 
converted to 3’-fluorine, 18F-FLT cannot be incorporated into DNA and is trapped in 
cytosol(Seitz et al., 2002). Therefore, the rate-limiting step for 18F-FLT-PET imaging is 
phosphorylation by TK1. TK1 has little activity in the quiescent cells but increased activity 
in proliferating cells, especially in the cells in S-phase(Munch-Petersen et al., 1995). 
In clinical studies, 18F-FLT-PET is commonly used in detecting brain tumor given its low 
uptake in the normal brain tissue(Spence et al., 2009). The high uptake in bone marrow and 
liver limits its diagnostic application especially in the assessment of liver and bone 
matastases. Besides, 18F-FLT-PET is not superior to 18F-FDG for cancer staging due to its low 
tumor-to-background ratios. Therefore, the imaging potential of 18F-FLT in breast cancer has 
been evaluated more often in the prediction and assessment of tumor response to a certain 
treatment. For instance, Pio et al scanned 14 breast cancer patients before and two weeks 
after the first cycle of the treatment, and found out that 18F-FLT uptake was strongly 
correlated with percentage change in CA27.29 tumor marker levels (r =0.79; p=0.001). In 
addition, the 18F-FLT uptake change after the chemotherapy course was predictive of late 
change in tumor size (r =0.74; p=0.01) as measured by CT scans(Pio et al., 2006). In a more 
recent study, Kenny et al assessed 18F-FLT response to a combined chemotherapy using 5-
fluorouracil, epirubicin, and cyclophosphamide in 13 breast cancer patients with 17 discrete 
lesions. Their observations indicated a significant difference in 18F-FLT uptake change 
between the responders and non-responders. The average decrease in responding lesions at 
90 min were 41.3% for SUV and 52.9% for Ki (net irreversible plasma to tumor transfer 
constant), while those of non-responding lesions were 3.1% and 1.9%, respectively(Kenny et 
al., 2007). 
To meet the clinical application needs, however, significant improvements are required 
in18F-FLT radiosynthesis. So far, there are two synthesis methods using different precursors, 
but neither could achieve an optimal radiochemical yield within a short preparation time. 
By using precursor 3’-O-nosyl thymidine with its pyrimidine ring protected with N-BOC, 
Yun et al achieved a high radiochemical yield of 42±5.4% within 60 min in a radiochemical 
purity >97%(Yun et al., 2003). On the other hand, Machulla et al used 5’-O-(4,4’-
dimethoxytriphenylmethyl)-2,3’-anhydrothymidine (DMTThy) as the precursor to achieve 
the preparation time within 10 min at 160oC, however, the radiochemical yield was only 
14.3±3.3%(Machulla et al., 2000). 
4.4 Radiotracers imaging amino acid transporters and protein synthesis 
11C/99mTc-methionine 
Amino acid-based radiotracers are developed for tumor imaging based on the fact that 
tumor cells uptake and consume more amino acids to sustain their uncontrolled growth 
compared with the normal cells. Most of those radiotracers are reported to enter the tumor 
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cells via amino acid transporters, such as Na+-independent L-type amino acid transporter 
system LAT, and Na+-dependent transport systems A and B0(Jager et al., 2001). 
11C-methionine (11C-MET) can be synthesized with an automation module within 20 min 
after the bombardment in a radiochemical yield of >30%. The specific activity was 3.3 
Ci/mmol, and the radiochemical purity was >96%(Davis et al., 1982). 11C-MET has recently 
been evaluated by Lindholm et al for its potential in assessing early response to therapy in 
advanced breast cancer. Twenty-five out of 26 metastatic sites from 13 patients could be 
detected by 11C-MET-PET. The standard uptake value (SUV) in all six responding metastatic 
sites decreased by 30-54% (P <0.05), while that of non-responding sites did not decrease 
significantly (11-13%; P =NS)(Lindholm et al., 2009). 
On the other hand, 99mTc-labeld methionine has also been successfully used to detect breast 
cancer in a recent clinical trial performed by Sharma et al. 99mTc-methionine is proven to 
have the same biological properties as 11C-methionine, but the longer half-life of in-house 
generator-produced radioisotope 99mTc (t1/2 =6 h) provides a more simple and affordable 
way to image breast tumor using conventional scintimammography. 99mTc-methionine was 
synthesized by conjugating methionine with diethylene triamine pentaacetic acid and 99mTc, 
and the radiochemical yield was >95%. The sensitivity, specificity, and positive predictive 
value of 99mTc-methionine in this clinical trial with 47 patients were 87.8%, 92.8%, and 96.6%, 
respectively(Sharma et al., 2009). 
4.5 Radiotracers imaging angiogenesis 
Radiolabeled RGD peptides  
Angiogenesis, which stands for the formation of new blood vessels, is required for solid tumor 
to obtain essential oxygen and nutrients for growth. Integrins, one kind of glycoproteins 
located on the cell surface, are extremely important in angiogenesis to mediate cell-cell or cell-
extracellular matrix interactions(Takada et al., 2007). There are 24 integrins being reported up 
to date; among these, integrin ┙V┚3 is the best-studied subtype as the molecular marker for 
targeting angiogenic cascade. A small peptide sequence consists of arginine-glycine-aspartic 
acid (RGD) has been identified as the motif of integrins for binding to their ┙V subunit, 
including ┙V┚3(Ruoslahti & Pierschbacher, 1987). Several radiolabled RGD peptides have been 
developed to image breast tumors in human. Here, two major radiotracers are introduced, 
99mTc-NC100692 for SPECT imaging and 18F-galacto-RGD for PET imaging. 
NC100692 is a cyclic synthetic ligand containing RGD binding site with high affinity to ┙V┚3 
and ┙V┚5, which are upregulated during angiogenesis. 99mTc-NC100692 is currently under 
Phase II clinical trial by GE healthcare. In the study performed by Bach-Gansmo et al, 19 out 
of 22 malignant lesions from 20 breast cancer patients were detected by 99mTc-NC100692 
scintigraphy (86%)(Bach-Gansmo et al., 2006). In the Phase 2a study performed by Axelsson 
et al, 99mTc-NC100692 scintigraphy detected 1 out of 7 liver, 4 out of 5 lung, 8 out of 17 bone, 
and 1 out of 1 brain metastases in 10 patients with breast cancer(Axelsson et al., 2010). 
18F-galacto-RGD was first developed by Haubner et al in 2001(Haubner et al., 2001). By 
adding a sugar amino acid to the RGD peptide, the lipophilicity of the tracer could be 
reduced, which resulted in less uptake in liver and increased uptake in tumor. The overall 
radiochemical yield of 18F-galacto-RGD was 29±5%, and the purity was >98%(Haubner et al., 
2004). Beer et al performed 18F-galacto-RGD-PET in 16 patients with invasive ductal breast 
cancer in 2007. All of the invasive carcinomas could be identified (SUV = 3.6±1.8, tumor-to-
muscle ratios = 6.2±2.2), however, only 3 out of 8 lymph node metastases were detected(Beer 
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et al., 2008). In addition, 18F-galacto-RGD images were found to represent the mixture of 
┙V┚3 expressed in both tumor cells and endothelial cells, so the agent was not tumor 
specific. According to several preclinical and clinical studies, 18F-galacto-RGD-PET may not 
be suitable to differentiate tumor from inflammation, because ┙V┚3 is also highly expressed 
in the macrophages and other inflammatory lesions(Gaertner et al., 2010). 
4.6 Radiotracers for bone scan 
99mTc-methylene diphosphonate (99mTc-MDP) 
The most common site of breast cancer metastases is bone, mainly spine and pelvis. The 
distribution of bone metastases is a prognostic factor of breast cancer(Hamaoka et al., 2004). 
Bone scintigraphy using 99mTc-methylene diphosphonate (99mTc-MDP) is the standard initial 
imaging technique to assess bone metastases. The uptake mechanism of 99mTc-MDP in bone 
is the chemical absorption onto the surface of hydroxyapatite and then incorporation into 
the crystalline structure of hydroxyapatite(Kanishi, 1993). The specificity and sensitivity of 
99mTc-MDP bone scintigraphy for breast cancer bone metastases are 78-100% and 62-100%, 
respectively(Hamaoka et al., 2004). Since its detection rate in early stages breast cancer 
patient is very low (0.82% for stage I disease), the routine screening is only recommended to 
patients in advanced stages(Yeh et al., 1995). In addition, 99mTc-MDP bone scintigraphy may 
not be suitable to monitor hormonal therapy response because of the increased 99mTc-MDP 
uptake caused by new bone formation during the repair process after the therapy (“flare 
phenomenon”)(Mortimer et al., 2001). In summary, given its high availability and 
affordability, as well as its rapid generation of whole-body images, the advantage of bone 
scintigraphy is rather for screening the patient with late stage (III and IV) breast cancer, than 
diagnosis. Instead of bone scintigraphy, 99mTc-MDP using SPECT or SPECT/CT is more 
suitable for the diagnosis of breast cancer bone metastases given its higher resolution and 
accuracy. The specificity and sensitivity of 99mTc-MDP-SPECT are 91-93% and 87-92%, 
respectively(Han et al., 1998).  
18F-fluoride 
18F-labeled sodium fluoride (18F-fluoride) is a non-specific PET radiotracer for whole-body 
bone metastases imaging. Its uptake is via the exchange of hydroxyl ions in the 
hydroxyapatite crystal, mainly at the surface of the skeleton(Hawkins et al., 1992). 18F-
fluoride PET has higher resolution, sensitivity (99%) and specificity (97%) than 99mTc-MDP-
SPECT(Even-Sapir et al., 2004). Besides, the absolute uptake of 18F-fluoride in normal bone 
was twice as high as that of 99mTc-MDP. Although 18F-fluoride is not tumor-specific, it can 
differentiate tumor from benign tissues better than 99mTc-MDP bone scintigraphy thanks to 
the superior spatial resolution of PET scanner. Among all the benign abnormalities detected 
by 18F-fluoride PET, 80% are caused by endplate factures and arthritis of the articular facets, 
both of which have a typical uptake pattern of 18F-fluoride(Schirrmeister et al., 1998). In 18F-
fluoride PET images, lesions that are not located at joint surfaces are suspicious for 
metastases. In addition, the lesions that do not show the typical pattern of endplate fracture, 
osteophytes, or serial rib fractures are suspicious for metastases as well. 
5. Conclusion 
Molecular imaging such as PET and SPECT plays an important role in non-invasive breast 
cancer diagnosis, staging, and treatment response evaluation. In this chapter, we have 
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focused on introducing the radiotracers commonly used in molecular imaging of breast 
cancer, according to the classification of the tumor-specific characteristics to which they are 
targeting. To date, 18F-FDG and 99mTc-sestamibi are still the two most extensively used 
radiopharmaceuticals in breast cancer for PET and ┛-imaging, respectively. The advances in 
molecular cancer biology have led to an increased understanding of the cancer biomarkers 
that contribute to cancer progression, and thus led to the rapid development of more 
personalized and specifically tumor-targeted treatments. There is an increasing demand on 
molecular imaging and tracer development to help direct and assess the treatment response 
in an early stage.   
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